Phase III data on Belviq published in Obesity - Eisai/Arena Pharma

Eisai and Arena Pharmaceuticals have announced that an article based on post-hoc analyses from the three pivotal Phase III trials of Belviq (lorcaserin) was recently published in the online issue of Obesity. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Data shows that lorcaserin patients with a Week 12 response achieved mean Week 52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving at least 5% and at least 10% weight loss at W52 were 85.5% and 49.8% (without diabetes), and 70.5% and 35.9% (with diabetes).

Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent-to-treat population, consistent with greater weight loss. See: "Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes" Steven R. Smith et al. Obesity 18 JUL 2014, DOI: 10.1002/oby.20841